Trioctyl Trimellitate(TOTM) is a fire-proof and lasting primary plasticizer, with the good points of polyester plasticizer and monomer plasticizer,suitable for PVC, cellulose nitrate,ethylcellulose and poly (methyl methacrylate) etc,it's electrical property is pretty good and mainly used in the fire-proof electrical wires and cables of 105ºC level and other fire-proof and lasting panels,sheet materials,seating gaskets and so on. Trioctyl Trimellitate,99.5%Trioctyl Trimellitate,Plasticizer Oil Totm,Substitute Plasticizer Totm Dongying Kexing International Trade Co., Ltd , https://www.kxiechem.com
At the CPhI show in Frankfurt this year, the most notable is the outsourcing service industry in Europe. At this point, people have an overall understanding of the industry. According to data provided by PharmSource, Europe's pharmaceutical outsourcing service market is US$5.75 billion, which accounts for 55% of the global pharmaceutical outsourcing market.
Although the PharmSource outsourcing database included more than 160 leading outsourcing companies, it was impressive that most of the top 10 of outsourcing service providers came from Europe (see table). In the current global economic downturn and difficult industrial environment, the success of the European formulation outsourcing service providers is worthy of our reference.
Unfavorable factors
Under the adverse market conditions, European formulation outsourcing providers face many obstacles, including:
â— Sales environment: The price of new drugs and the acceptance of consumers are strictly controlled by European governments. Under such circumstances, pharmaceutical companies are under pressure to reduce costs as much as possible. This can be seen from the profits of European outsourcing service providers. Come out.
â— Exchange Rate: The low exchange rate between the US dollar and the Euro has made European outsourcing service providers more and more disadvantageous when competing with American counterparts.
â— Overcapacity: Due to labor law issues, enterprises will face high costs in shutting down redundant production bases, which will allow outsourcing service providers to sell excess capacity just like large pharmaceutical companies. As another alternative, European outsourcing service providers will sell production bases to some management organizations at a low price.
â— Regional prejudices: Although success has been achieved in maintaining growth within the EU, European outsourcing service companies still face regional prejudices. For example, French pharmaceutical companies tend to favor French outsourcing providers, and similarly, Spanish companies tend to outsource Spanish service providers.
factor of success
In spite of all the above-mentioned unfavorable factors, European large-scale outsourcing service providers have succeeded. The main factors of success for these companies are:
â— Establish good links with large pharmaceutical companies. The largest outsourcing service provider in Europe has established a long-term cooperation relationship with the global pharmaceutical giants, which will reduce regional prejudice. When outsourcing service providers obtained their redundant production bases from large-scale pharmaceutical companies, they obtained contracts for the production of legacy products for large-scale pharmaceutical companies for many years, and thus were inextricably linked with these large-scale pharmaceutical companies.
â— Perfect regional network. Most outsourcing service providers have set up production bases in many countries, so that these companies are considered as regional companies looking for potential customers in these countries. For example, an outsourcing service provider stated that since the acquisition of a French-based production facility for parenteral administration in 2007, French pharmaceutical companies have become more willing to conduct business cooperation with them, even if these parts of Europe are more suitable for these French companies. Outsourcing service provider for pharmaceutical companies.
â— Strong professional production capacity. Many outsourcing service providers have the special production capacity to process the mixture that needs to be separated in addition to the production capacity of conventional dosage forms.
â—Import obstacles. Due to the different GMP regulations, imports of medicines from countries outside Europe are faced with major obstacles, which has benefited many outsourcing service providers in Europe. In addition, regional production is more beneficial to clinical supplies.
â— Efficiency. At present, the entire industry has a feeling that many European outsourcing service providers are more efficient than outsourcing service providers in other places. Considering the level of investment and employees' perspective, this high efficiency helps European outsourcing providers overcome other cost disadvantages.
Mobile supply base
The difference between European outsourcing service providers and outsourcing service providers in other regions lies in the level of M&A and acquisition capabilities. Many European pharmaceutical outsourcing service providers have relatively large steps in supplementing production sites or joint production sites, especially for private companies that are interested in long-term outsourcing services. In recent years, the major activities carried out by European formulation outsourcing providers include:
- Fareva, based in Paris, France, recently acquired its semi-solid and liquid production facility in Herouville, France, from GlaxoSmithKline and obtained its production site in Feucht, Germany, from Pfizer. In the past three years, Fareva has completed a leap in commission revenue from zero to nearly 300 million U.S. dollars.
- Swiss Caps, a soft capsule manufacturer recently located in Switzerland, and Dragenopharm, a solids manufacturer based in Germany, merged and established Aenova, headquartered in Tittmoning, Germany. The merger of the two companies was promoted by Bridgepoint, a private company that owns these two companies.
- Haupt Pharmaceuticals, based in Berlin, Germany, became a $250 million company after acquiring Amareg and Wulfing, two other outsourcing providers.
- Recipharm, based in Haninge, Sweden, has acquired injection production sites in France, the United Kingdom and Switzerland in order to complement its solid formulation production base in Sweden.
Go global
As companies grow, these companies are also seeking a path to globalization. Some of these companies are looking forward to their first FDA license. Vetter and Haupt, based in Ravensburg, Germany, have established a sales company in the United States. Nextpharm, based in Send, United Kingdom, acquired the first outsourcing company in San Diego Bioserve in 2007. European outsourcing providers are looking forward to becoming one of the bidders for Catalent, a manufacturer of parenteral drugs in Northern California.
Overall, the situation of European preparation outsourcing providers now looks better. However, the major problem encountered is whether these well-behaved companies can continue to maintain. The leading market outsourcing service providers in Europe still need to continue their efforts to consolidate their current superior position.
European outsourcing advantages increase steadily and account for 55% of global outsourcing market
Despite the current global economic downturn and difficult industrial environment, European formulation outsourcing service providers are enjoying considerable returns. Analysis and summary of their successful experience, it is worth our country's pharmaceutical companies for reference